Search
Nektar Therapeutics
NKTRAdd to Watchlist
60.980USD
+0.060+0.10%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
2.06BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Nektar Therapeutics is 8.80, ranking 57 out of 389 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 121.00 and a low of 98.00.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
153.250
Target Price
+151.56%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Nektar Therapeutics
NKTR
10
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Nektar Therapeutics's expected revenue for the next quarter?
Nektar Therapeutics's expected revenue is 10.38M.
What is Nektar Therapeutics's price target?
Analysts forecast that Nektar Therapeutics's price target is USD 105.00, with the highest forecast at USD 121.00 and the lowest forecast at USD 98.00.
How have Nektar TherapeuticsNKTR's recent earnings per share performed?
The market expectation was USD -1.82, while Nektar TherapeuticsNKTR's earnings per share (EPS) for the previous quarter was USD -1.77. EPS for the next quarter is expected at USD -2.04.
What is the analyst rating for Nektar Therapeutics?
Based on the ratings of Nektar Therapeutics's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
